These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20594854)

  • 1. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
    Sughrue ME; McDermott M; Blevins LS
    J Clin Neurosci; 2010 Oct; 17(10):1331-4. PubMed ID: 20594854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
    Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
    Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
    Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
    Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
    Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
    Marik PE; Rivera R
    Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
    Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA
    Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Annane D; Decaux G; Smith N;
    Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
    Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
    Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
    Human T; Onuoha A; Diringer M; Dhar R
    J Crit Care; 2012 Dec; 27(6):745.e1-5. PubMed ID: 22520494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
    Ferguson-Myrthil N
    Cardiol Rev; 2010; 18(6):313-21. PubMed ID: 20926941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conivaptan for hyponatremia in the neurocritical care unit.
    Wright WL; Asbury WH; Gilmore JL; Samuels OB
    Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous conivaptan.
    Moen MD; Keating GM
    Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
    Kalra S; Efrati S; Arthur JM; Oliven A; Velez JC; McNutt BE; Klasen S; Abeyratne A
    Am J Health Syst Pharm; 2011 Apr; 68(7):590-8. PubMed ID: 21411800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C; Lesch C; Berger K
    Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of conivaptan for the treatment of symptomatic hyponatremia in a patient with acute decompensated heart failure.
    Pinner NA; Oliphant CS; Hopkins JP
    Am J Health Syst Pharm; 2010 Jun; 67(12):1011-5. PubMed ID: 20516472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.